

REMARKS

The parent application was filed with a total of 23 Claims. In a Restriction Requirement of approximately May 29, 2001, Examiner Leffers indicated that the parent application was subject to a restriction between 38 Groups. Each sequence (SEQ ID NOS:1-38) listed in Table 1 was placed in a separate Group. However, the Examiner indicated that claims directed to the method from producing a protein in a host cell (claims 1 - 16); claims directed to an expression vector (claims 17 - 20); and claims directed to a host cell (claims 21 - 23) would be examined together. In the parent application, SEQ ID NOS: 2-5 were examined.

In the present amendments, SEQ ID NOs: 1 - 38 have been renumbered SEQ ID NOs: 3 - 40, and reference is made to the sequence listing and the amendments concurrently filed herewith. Applicants note that the Examiner did not include SEQ ID NO: 2 in the restriction. SEQ ID NO: 2 is not listed in Table 1 however, it is designated in the specification as a preferred embodiment. SEQ ID NO: 2 has the amino acid sequence of EVETKSAGGIVLTGSAAA. Numerous sequences as listed in Table 1 are very similar and Applicants believe it would not be a burden for all of these sequences to be examined together, and at a minimum for at least some of the sequences to be examined together. For example, using the amended sequence identifiers, SEQ ID NOS:21 and 22 should be examined together, as they are very similar sequences.

Therefore, Applicants respectfully submit that Groups 21 and 22 should be examined together. Herein, Applicants have amended the Claims to recite these sequences in the present Divisional application.


CONCLUSION

Applicants respectfully request entry of the above Preliminary Amendment. Pursuant to 35 U.S.C. § 120, the Specification has been amended to recite the Divisional status of this application, and its relationship to the previous application filed by Applicants, as well as the status of Government funding. Applicants have amended the Specification to include the sequence identifiers for various polynucleotide and amino acid sequences as disclosed in the application. Additionally the sequence identifiers for the chaperonin binding domains as listed in Table 1 have been included to correctly reflect SEQ ID NOs: 3 - 40 as opposed to SEQ ID NOs: 1 - 38. Applicants respectfully request that the application also be amended to include the sequence listing in the Specification after page 19. The paper copy of the sequence listing and the diskette are concurrently filed herewith. No new matter has been added in the present amendments.

If the Examiner has any questions regarding the present application he or she is encouraged to contact the undersigned.

Respectfully submitted,

Date: November 13, 2003


Kamrin T. MacKnight
Registration No. 38,230

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304
Tel: 650-846-5838
Fax: 650-845-6504